AtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression

AtaiBeckley Inc. (ATAI) — AtaiBeckley announced the last patient was dosed in Elumina, its Phase 2b trial of VLS-01, an oral transmucosal DMT film, in adults with treatment-resistant depression, with topline data expected in Q4 2026.

Pending a supportive readout, the company plans to advance VLS-01 into a Phase 3 program in major depressive disorder. The milestone progresses one of AtaiBeckley's wholly owned pipeline assets alongside its lead BPL-003 program.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.